Patents by Inventor Narendra MAHESHRI
Narendra MAHESHRI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210077552Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: ApplicationFiled: November 20, 2020Publication date: March 18, 2021Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
-
Patent number: 10900886Abstract: The method, device, and system relate to particle analysis, and in particular, to a microfluidic device designed for trapping particles for analysis. Particles include beads and cells.Type: GrantFiled: April 20, 2018Date of Patent: January 26, 2021Assignee: EMD Millipore CorporationInventors: Philip Janmin Lee, Paul Ju-Sung Hung, Narendra Maheshri
-
Publication number: 20190169237Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: ApplicationFiled: February 13, 2019Publication date: June 6, 2019Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
-
Patent number: 10214566Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provide methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: GrantFiled: August 5, 2016Date of Patent: February 26, 2019Assignee: The Regents of the University of CaliforniaInventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
-
Publication number: 20180289757Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: ApplicationFiled: June 18, 2018Publication date: October 11, 2018Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
-
Publication number: 20180275043Abstract: The method, device, and system relate to particle analysis, and in particular, to a microfluidic device designed for trapping particles for analysis. Particles include beads and cells.Type: ApplicationFiled: April 20, 2018Publication date: September 27, 2018Inventors: Philip Janmin Lee, Paul Ju-Sung Hung, Narendra Maheshri
-
Patent number: 10054536Abstract: The device and method relate to microfluidic particle analysis. The device is designed for trapping particles for solution analysis. Exemplary particles include beads and cells. The device has a microfluidics body, and a microfluidics channel formed in the body for receiving particles at an upstream region thereof. The channel has a deformable wall portion that defines a particle-capture region, and is responsive to a change in fluid pressure applied thereto, to selectively vary the particle-flow dimensions of the capture region. In this way, particles having a given size may be selectively retained in the capture region. In one embodiment, the deformable wall portion is expandable in response to a positive fluid pressure applied within the channel. In another embodiment, the deformable wall portion is expandable in response to a negative pressure applied to a cavity communicating with the wall portion, external to the channel.Type: GrantFiled: May 24, 2016Date of Patent: August 21, 2018Assignee: EMD Millipore CorporationInventors: Philip Janmin Lee, Paul Ju-Sung Hung, Narendra Maheshri
-
Patent number: 10046016Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: GrantFiled: July 28, 2014Date of Patent: August 14, 2018Assignees: The Regents of the University of California, Integrative Gene TherapeuticsInventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
-
Publication number: 20160340393Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: ApplicationFiled: August 5, 2016Publication date: November 24, 2016Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
-
Publication number: 20160327470Abstract: The method, device, and system relate to particle analysis, and in particular, to a microfluidic device designed for trapping particles for analysis. Particles include beads and cells.Type: ApplicationFiled: May 24, 2016Publication date: November 10, 2016Inventors: Philip Janmin Lee, Paul Ju-Sung Hung, Narendra Maheshri
-
Patent number: 9441244Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: GrantFiled: June 28, 2004Date of Patent: September 13, 2016Assignee: The Regents of the University of CaliforniaInventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
-
Patent number: 9354156Abstract: The method, device, and system relate to particle analysis, and in particular, to a microfluidic device designed for trapping particles for analysis. Particles include beads and cells.Type: GrantFiled: January 25, 2008Date of Patent: May 31, 2016Assignee: EMD Millipore CorporationInventors: Philip Janmin Lee, Paul Ju-Sung Hung, Narendra Maheshri
-
Patent number: 9233131Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: GrantFiled: November 24, 2008Date of Patent: January 12, 2016Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
-
Publication number: 20150132262Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: ApplicationFiled: July 28, 2014Publication date: May 14, 2015Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
-
Publication number: 20090202490Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: ApplicationFiled: November 24, 2008Publication date: August 13, 2009Inventors: David V. SCHAFFER, Brian KASPAR, Narendra MAHESHRI
-
Publication number: 20080194012Abstract: The method, device, and system relate to particle analysis, and in particular, to a microfluidic device designed for trapping particles for analysis. Particles include beads and cells.Type: ApplicationFiled: January 25, 2008Publication date: August 14, 2008Applicant: CellASIC CorporationInventors: Philip Janmin Lee, Paul Ju-Sung Hung, Narendra Maheshri
-
Publication number: 20050053922Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: ApplicationFiled: June 28, 2004Publication date: March 10, 2005Inventors: David Schaffer, Brian Kaspar, Narendra Maheshri